Alembic Pharma gets USFDA nod for diabetes drug

New Delhi: Alembic Pharmaceuticals said Friday it has received tentative approval from the US health regulator to market Alogliptin and Metformin Hydrochloride tablets, an anti-diabetes medication, in the US market. The company’s product is a generic version of Takeda Pharma USA’s Kazano tablets, Alembic Pharmaceuticals said in a regulatory filing.

Alogliptin and Metformin Hydrochloride tablets had an estimated market size of USD 22.5 million in the US for 12 months ending December 2017, according to the market data.

Alembic now has a total of 77 abbreviated new drug application (ANDA) approvals from the USFDA.

Shares of the company gained 1.17 per cent to settle at Rs 647.70 apiece on BSE Friday.

  • Related Posts

    FSSAI prohibits Dabur from selling food products with ‘100%’ claims

    FSSAI asserted that the use of the 100% claims is in contravention of the FSS (Advertising & Claims) Regulations, 2018, as they are ambiguous, unverifiable and likely to mislead consumers…

    ORSL reinforces its commitment to improve diarrhoeal prevention in children

    Makers of ORSL, a leading oral rehydration salts (ORS) brand based on the World Health Organization (WHO) formula, in partnership with Population Services International India (PSI India), reaffirmed its commitment…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    FSSAI prohibits Dabur from selling food products with ‘100%’ claims

    FSSAI prohibits Dabur from selling food products with ‘100%’ claims

    ORSL reinforces its commitment to improve diarrhoeal prevention in children

    ORSL reinforces its commitment to improve diarrhoeal prevention in children

    ‘Donors got mixer grinders, cash’: blood banks in Bengal under scanner over ‘illegal’ sale to other States

    ‘Donors got mixer grinders, cash’: blood banks in Bengal under scanner over ‘illegal’ sale to other States

    CREATE Medicines expands targeted in vivo CAR platform through strategic research collaboration and exclusive license pact with Monash University

    CREATE Medicines expands targeted in vivo CAR platform through strategic research collaboration and exclusive license pact with Monash University

    CBN Dismantles Major Inter-State Counterfeit Drug Network In Bihar Under ‘Operation Vajra’; Mastermind Arrested

    CBN Dismantles Major Inter-State Counterfeit Drug Network In Bihar Under ‘Operation Vajra’; Mastermind Arrested

    Ministry of Ayush signs MoU with IndiaAI to harness AI for the future of traditional medicine

    Ministry of Ayush signs MoU with IndiaAI to harness AI for the future of traditional medicine